Emerging data suggest Retatrutide , a dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , could provide a significant step forward for weight treatment. Preliminary human tests have indicated impressive decreases in body fat , potentially surpassing current wei